These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14634965)

  • 1. [Side effects and toxicity of immunosuppressive agents].
    Salvadori M; Bertoni E
    G Ital Nefrol; 2003; 20(5):490-502. PubMed ID: 14634965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
    Caletti C; Granata S; Tomei P; Lupo A; Zaza G
    G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus.
    Prokai A; Fekete A; Pasti K; Rusai K; Banki NF; Reusz G; Szabo AJ
    Pediatr Diabetes; 2012 Feb; 13(1):81-91. PubMed ID: 21595806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation.
    Rangel EB
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1531-48. PubMed ID: 22978385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Posttransplant diabetes. Metabolic consequences of posttransplant immunosuppressive treatment].
    Christiansen E
    Ugeskr Laeger; 2007 Jun; 169(24):2309-11. PubMed ID: 17594845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttransplant diabetes mellitus after kidney transplantation with different immunosuppressive agents.
    Romagnoli J; Citterio F; Violi P; Nanni G; Castagneto M
    Transplant Proc; 2004 Apr; 36(3):690-1. PubMed ID: 15110632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
    Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus: defining nephrotoxicity in the renal transplant recipient.
    Tomlanovich SJ; Vincenti F
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):198-9. PubMed ID: 17699406
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients.
    Hakeam HA; Al-Jedai AH; Raza SM; Hamawi K
    Ann Transplant; 2008; 13(2):46-53. PubMed ID: 18566560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimization and withdrawal of steroids in pancreas and islet transplantation.
    Mineo D; Sageshima J; Burke GW; Ricordi C
    Transpl Int; 2009 Jan; 22(1):20-37. PubMed ID: 18855850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
    Roque E J; Ríos M G; Vignolo A P; Pinochet V C; Schultz M; Humeres A R; Delucchi A; Rius A M; Hepp K J
    Rev Med Chil; 2008 May; 136(5):631-6. PubMed ID: 18769812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
    Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
    Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of sirolimus in renal transplantation.
    Halleck F; Duerr M; Waiser J; Huber L; Matz M; Brakemeier S; Liefeldt L; Neumayer HH; Budde K
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1337-56. PubMed ID: 22928953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus in pancreas transplant: a focus on toxicity, diabetogenic effect and drug-drug interactions.
    Rangel EB
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1585-605. PubMed ID: 25255841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving tolerability of immunosuppressive regimens.
    MacDonald A
    Transplantation; 2001 Dec; 72(12 Suppl):S105-12. PubMed ID: 11833142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?
    Zeier M; Van Der Giet M
    Transpl Int; 2011 Jan; 24(1):30-42. PubMed ID: 20642495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
    Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.